Arvinas to present preclinical data for arv-393 at the 2025 american society of hematology (ash) annual meeting

New haven, conn., nov. 03, 2025 (globe newswire) -- arvinas, inc. (nasdaq: arvn), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for protac bcl6 degrader arv-393, in combination with glofitamab, a cd20xcd3 bispecific antibody, will be presented in a poster presentation at the 2025 american society of hematology (ash) annual meeting, being held december 6–9, 2025, in orlando, florida.
ASH Ratings Summary
ASH Quant Ranking